8-pCPT-2'-O-Me-cAMP-AM is a cyclic AMP analogue, selectively activates Epac-Rap signaling pathway. 8-pCPT-2'-O-Me-cAMP-AM protects renal function by activating Epac from ischemia injury. 8-pCPT-2'-O-Me-cAMP-AM also stimulates insulin secretion by interaction with PKA pathway. In Vitro 8-pCPT-2'-O-Me-cAMP-AM (2.5 μM; 30 min) activates Epac and prevents adherens junction disassembly during hypoxia (60 min). 8-pCPT-2'-O-Me-cAMP-AM can cross the plasma membrane and is able to alter diverse cellular functions that include Rap1 GTPase activity, PKB, and ERK1/2 protein kinase activity, phospholipase C activity, Ca 2+ signaling, ion channel activity, exocytosis, cell adhesion, and gene expression. 8-pCPT-2'-O-Me-cAMP-AM stimulates insulin secretion with dose-dependent and glucose metabolism-dependent (0.1 or 1.11 mM) actions. 8-pCPT-2'-O-Me-cAMP-AM (20 μM) activates the cAMP reporter Epac1-camps, while 8-pCPT-2'-O-Me-cAMP doesn’t in INS-1 cells. 8-pCPT-2'-O-Me-cAMP-AM (0.3-3.0 μM; 0-300 sec) activates Epac1-camps in a dose- and time-dependent manner in high throughput assay. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo 8-pCPT-2'-O-Me-cAMP-AM (intrarenal injection; ) activates renal Rap1 and likely is caused by activation of Epac in the tubular epithelium . 8-pCPT-2'-O-Me-cAMP-AM preserves renal function by Epac activation and reduces tubular epithelial-cell stress during ischemia . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: IR injuried mouse model Dosage: 1.45 mM Administration: Intrarenal injection; mice were sacrificed at 24, 48, or 72 hours after ischemia Result: Protected renal injury during ischemia. Form:Oil